• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

PROPRANOLOL Drug Record

  • Summary
  • Interactions
  • Claims
  • PROPRANOLOL chembl:CHEMBL27 Approved

    Alternate Names:

    INDERIDE-80/25
    AY-64043-
    INDERIDE-40/25
    INDERAL
    PROPRANOLOL

    Drug Info:

    Drug Class anti-arrhythmia agents
    Drug Class antihypertensive agents
    Year of Approval 1967
    FDA Approval approved
    Drug Class Small Molecule
    Drug Indications for treatment of cancer cachexia
    (4 More Sources)

    Publications:

    Woiciechowsky et al., 2004, Brain-IL-1 beta triggers astrogliosis through induction of IL-6: inhibition by propranolol and IL-10., Med. Sci. Monit.
    MacDonald ML et al., 2006, Identifying off-target effects and hidden phenotypes of drugs in human cells., Nat Chem Biol
    el Tayar N et al., 1988, Modeling of beta-adrenoceptors based on molecular electrostatic potential studies of agonists and antagonists., J Med Chem
    Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
    Rouget et al., 2006, Stimulation of the ADRB3 adrenergic receptor induces relaxation of human placental arteries: influence of preeclampsia., Biol. Reprod.
    Isaza et al., 2005, Polymorphic variants of the beta2-adrenergic receptor (ADRB2) gene and ADRB2-related propanolol-induced dyslipidemia in the Colombian population., Methods Find Exp Clin Pharmacol
    Horinouchi et al., 2007, Different changes of plasma membrane beta-adrenoceptors in rat heart after chronic administration of propranolol, atenolol and bevantolol., Life Sci.
    Illingworth et al., 2006, Classical polarization in hybrid QM/MM methods., J Phys Chem A
    Lewis et al., 2004, Overexpression of beta 1-adrenoceptors in adult rat ventricular myocytes enhances CGP 12177A cardiostimulation: implications for 'putative' beta 4-adrenoceptor pharmacology., Br. J. Pharmacol.
    Rezmann-Vitti et al., 2004, Site-directed mutagenesis of the rat beta1-adrenoceptor. Involvement of Tyr356 (7.43) in (+/-)cyanopindolol but not (+/-)[125Iodo]cyanopindolol binding., Eur J Med Chem
    Yazawa et al., 2007, Verrucotoxin, a stonefish venom, modulates calcium channel activity in guinea-pig ventricular myocytes., Br. J. Pharmacol.
    D'Emanuele et al., 2004, The use of a dendrimer-propranolol prodrug to bypass efflux transporters and enhance oral bioavailability., J Control Release
    Kaliman et al., 1999, Regulation of delta-aminolevulinate synthase activity during the development of oxidative stress., Biochemistry Mosc.
    Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol
    Ward et al., 2004, Development of an in vivo preclinical screen model to estimate absorption and first-pass hepatic extraction of xenobiotics. II. Use of ketoconazole to identify P-glycoprotein/CYP3A-limited bioavailability in the monkey., Drug Metab. Dispos.
    Buchhorn et al., 2003, Effects of therapeutic beta blockade on myocardial function and cardiac remodelling in congenital cardiac disease., Cardiol Young
    Reid et al., 2005, Effects of a beta-blocker on bone turnover in normal postmenopausal women: a randomized controlled trial., J. Clin. Endocrinol. Metab.
    Van Hoomissen et al., 2004, Effects of beta-adrenoreceptor blockade during chronic exercise on contextual fear conditioning and mRNA for galanin and brain-derived neurotrophic factor., Behav. Neurosci.
    Kozawa et al., 2001, Stimulatory effect of basic fibroblast growth factor on induction of heat shock protein 27 in osteoblasts: role of protein kinase C., Arch. Biochem. Biophys.
    Hirose et al., 1997, Pituitary adenylate cyclase-activating polypeptide-27 causes a biphasic chronotropic effect and atrial fibrillation in autonomically decentralized, anesthetized dogs., J. Pharmacol. Exp. Ther.
  • PROPRANOLOL   ADCYAP1

    Interaction Score: 3.86

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    9353360


    Sources:
    NCI

  • PROPRANOLOL   HSPB2

    Interaction Score: 0.86

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    11368160


    Sources:
    NCI

  • PROPRANOLOL   ADRB1

    Interaction Score: 0.51

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Trial Name VT-122
    Novel drug target Established target

    PMIDs:
    16177222 17628611 14757703 11752352 15236843 17572694 2903243


    Sources:
    DTC TdgClinicalTrial TEND TTD

  • PROPRANOLOL   CCN2

    Interaction Score: 0.41

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    12691286


    Sources:
    NCI

  • PROPRANOLOL   BGLAP

    Interaction Score: 0.34

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15998769


    Sources:
    NCI

  • PROPRANOLOL   GFAP

    Interaction Score: 0.31

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15328477


    Sources:
    NCI

  • PROPRANOLOL   ADRB2

    Interaction Score: 0.3

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:

    PMIDs:
    16680159 2903243 11752352 16177222 16082424 17628611 16706406


    Sources:
    DTC TEND PharmGKB

  • PROPRANOLOL   BDNF

    Interaction Score: 0.12

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15598146


    Sources:
    NCI

  • PROPRANOLOL   G6PD

    Interaction Score: 0.11

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    10395986


    Sources:
    NCI

  • PROPRANOLOL   ABCB1

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15023456


    Sources:
    NCI PharmGKB

  • PROPRANOLOL   CYP2D6

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC FDA

  • PROPRANOLOL   CYP2C9

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC

  • PROPRANOLOL   CYP3A4

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300 14744938


    Sources:
    DTC NCI

  • PROPRANOLOL   CYP2C19

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC

  • PROPRANOLOL   CYP1A2

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC

  • PROPRANOLOL   EHMT2

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • TdgClinicalTrial: PROPRANOLOL

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications for treatment of cancer cachexia
    Drug Class Small Molecule
    FDA Approval approved

    Publications:

  • TEND: PROPRANOLOL

    • Version: 01-August-2011

    Alternate Names:

    Drug Info:
    Year of Approval 1967
    Drug Class antihypertensive agents
    Drug Class anti-arrhythmia agents

    Publications:

  • DTC: PROPRANOLOL

    • Version: 02-September-2020

    Alternate Names:
    CHEMBL27 ChEMBL Drug ID

    Drug Info:

    Publications:
    Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol
    el Tayar N et al., 1988, Modeling of beta-adrenoceptors based on molecular electrostatic potential studies of agonists and antagonists., J Med Chem
    MacDonald ML et al., 2006, Identifying off-target effects and hidden phenotypes of drugs in human cells., Nat Chem Biol

  • NCI: PROPRANOLOL

    • Version: 14-September-2017

    Alternate Names:
    C29382 NCI drug code

    Drug Info:

    Publications:
    Woiciechowsky et al., 2004, Brain-IL-1 beta triggers astrogliosis through induction of IL-6: inhibition by propranolol and IL-10., Med. Sci. Monit.
    Van Hoomissen et al., 2004, Effects of beta-adrenoreceptor blockade during chronic exercise on contextual fear conditioning and mRNA for galanin and brain-derived neurotrophic factor., Behav. Neurosci.
    Kozawa et al., 2001, Stimulatory effect of basic fibroblast growth factor on induction of heat shock protein 27 in osteoblasts: role of protein kinase C., Arch. Biochem. Biophys.

  • TTD: Propranolol

    • Version: 2020.06.01

    Alternate Names:
    D04JEE TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL27

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • PharmGKB: propranolol

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:

  • FDA: Propranolol

    • Version: 04-September-2020

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21